This webinar will review the latest approaches in the management of the immunosuppressed patient in the context of HBV reactivation, including screening, risk stratification and indication for antiviral treatment. The focus of management will be on both the oncologic and non-oncologic patient.
Wen‐Zhi Guo, Hong‐Bo Fang, Sheng‐Li Cao, San‐Yang Chen, Jie Li, Ji‐Hua Shi, Hong‐Wei Tang, Yi Zhang, Pei‐Hao Wen, Jia‐Kai Zhang, Zhi‐Hui Wang, Xiao‐Yi Shi, Chun Pang, Han Yang, Bo‐Wen Hu, Shui‐Jun Zhang – 8 August 2019
Feng Zhou, Jianghua Zhou, Wenxin Wang, Xiao‐Jing Zhang, Yan‐Xiao Ji, Peng Zhang, Zhi‐Gang She, Lihua Zhu, Jingjing Cai, Hongliang Li – 7 August 2019
Yuankai Wu, Yee Hui Yeo, Mindie H. Nguyen, Ramsey C. Cheung – 7 August 2019
Kavita Radhakrishnan, Adrian M. Di Bisceglie, K. Rajender Reddy, Joseph K. Lim, Josh Levitsky, Mohamed A. Hassan, Jama M. Darling, Jordan J. Feld, Lucy Akushevich, Monika Vainorius, David R. Nelson, Michael W. Fried, Robert S. Brown, Norah A. Terrault – 7 August 2019 – Recent studies have suggested a negative impact of hepatocellular carcinoma (HCC) on sustained virologic response (SVR) to hepatitis C virus (HCV) direct acting antivirals (DAAs).
Hassan Azhari, Mark G. Swain – 7 August 2019
Jérôme Boursier, Sven Francque – 5 August 2019
Ying Zhou, Bingning Dong, Kang Ho Kim, Sungwoo Choi, Zhen Sun, Nan Wu, Yifan Wu, Jessica Scott, David D. Moore – 5 August 2019
Hong Min Wu, Tae Hyun Kim, Ayoung Kim, Ja Hyun Koo, Min Sung Joo, Sang Geon Kim – 5 August 2019 – Liver X receptor‐alpha (LXRα) acts as a double‐edged sword in different biological situations. Given the elusive role of LXRα in hepatocyte viability, this study investigated whether LXRα protects hepatocytes from injurious stimuli and the underlying basis. LXRα activation prevented hepatocyte apoptosis from CCl4 challenges in mice.